Using Mesenchymal Stromal Cells to Treat Graft Versus Host Disease in Children
Author Information
Author(s): Wernicke Caroline M, Grunewald Thomas G, Hendrik Juenger, Kuci Selim, Kuci Zyrafete, Koehl Ulrike, Mueller Ingo, Doering Michaela, Peters Christina, Lawitschka Anita, Kolb Hans-Jochem, Bader Peter, Burdach Stefan, Luettichau Irene
Primary Institution: Children's Cancer Research and Roman Herzog Comprehensive Cancer Center, Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München
Hypothesis
Can mesenchymal stromal cells (MSCs) effectively treat steroid-refractory graft versus host disease (GvHD) in pediatric patients?
Conclusion
The study suggests that MSCs are a promising treatment option for children with steroid-refractory GvHD, showing better response rates compared to adults.
Supporting Evidence
- Children with steroid-refractory GvHD showed a higher response rate to MSC treatment compared to adults.
- The overall response rate to MSC treatment was 73.8% across the studies reviewed.
- Complete response rates were 57.4% in children versus 45.1% in adults.
- Two pediatric cases demonstrated significant improvement after MSC treatment.
Takeaway
Doctors are trying a new treatment using special cells called MSCs to help kids who are very sick from a condition called GvHD, and it seems to be working better for them than for adults.
Methodology
The study includes a review of literature and a meta-analysis of clinical studies on MSCs treatment for GvHD in children and adults.
Potential Biases
There may be biases in the reporting of outcomes due to the heterogeneity of studies included in the meta-analysis.
Limitations
The efficacy of MSCs in treating GvHD varies due to differences in MSC production and processing methods.
Participant Demographics
The study analyzed data from 183 patients, including 61 children and 122 adults.
Statistical Information
P-Value
0.037
Confidence Interval
95% CI 0.94 - 4.37
Statistical Significance
p=0.037
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website